BRIEF published on 10/09/2024 at 17:50, 1 month 11 days ago Valbiotis: Information on voting rights and shares, September 2024 Share Capital Voting Rights Euronext Growth Valbiotis Threshold Crossings
BRIEF published on 10/09/2024 at 17:50, 1 month 11 days ago Update on Valbiotis voting rights for September 2024 Share Capital Voting Rights Actions Euronext Growth Valbiotis
BRIEF published on 09/12/2024 at 17:50, 2 months 8 days ago VALBIOTIS: Monthly information on voting rights and shares in August 2024 Share Capital Voting Rights Actions Euronext Growth Valbiotis
BRIEF published on 09/12/2024 at 17:50, 2 months 8 days ago Valbiotis: Monthly Information on Voting Rights and Shares - August 2024 Voting Rights Euronext Actions Transparency Valbiotis
BRIEF published on 09/05/2024 at 17:45, 2 months 15 days ago Valbiotis to Present at 2024 EASD Congress Valbiotis TOTUM•63 Prediabetes Type 2 Diabetes EASD 2024
PRESS RELEASE published on 09/05/2024 at 17:40, 2 months 15 days ago VALBIOTIS : Oral presentation at the 2024 EASD congress Valbiotis selected to present clinical results from TOTUM 63 Phase II/III clinical study in prediabetes and type 2 diabetes at 2024 EASD congress. Innovative non-drug solution against type 2 diabetes epidemic Valbiotis Prediabetes TOTUM 63 Clinical Results Type 2 Diabetes
BRIEF published on 08/12/2024 at 08:05, 3 months 9 days ago VALBIOTIS SA: Total number of voting rights and shares - July 2024 Voting Rights Actions Valbiotis Financial Market Threshold Crossings
BRIEF published on 08/12/2024 at 08:05, 3 months 9 days ago VALBIOTIS SA: Information on voting rights and shares - July 2024 Share Capital Voting Rights Actions Euronext Growth Valbiotis
BRIEF published on 07/11/2024 at 08:35, 4 months 10 days ago Valbiotis: Half-yearly review of the liquidity contract Liquidity Contract PORTZAMPARC Half-yearly Report Valbiotis Valbiotis Titles
BRIEF published on 07/11/2024 at 08:35, 4 months 10 days ago Half-yearly review of the Valbiotis liquidity contract Liquidity Contract PORTZAMPARC Valbiotis Food Supplements Half-yearly Review
Published on 11/21/2024 at 14:00, 11 minutes ago Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 11 minutes ago Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 11 minutes ago Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 13:30, 41 minutes ago AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 12:35, 1 hour 35 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 55 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 7 hours 13 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 51 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 26 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 26 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
